FTC settles Hikma Roxane competition concerns

The US Federal Trade Commission (FTC) has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.

The FTC made the announcement yesterday, May 5. The order was approved in a 3-0 vote.

Under the terms of the order, Hikma must sell the rights and assets to two generic drugs, prednisone tablets and lithium carbonate capsules, to Renaissance Pharma.

Hikma is also required to relinquish its rights to market Tambocor (flecainide acetate) tablets in the US and sell its equity interest in its drug development partner, India-based Unimark Remedies.

Under the order, Hikma has 20 days to comply with the terms.